JDD January 2026 Issue Highlights
Welcome to "JDD January 2026 Issue Highlights," your guided tour through this month's must-read studies, curated by the Journal of Drugs in Dermatology Editorial Team. This issue carries a Special Focus on Aesthetic Treatments, bringing together practical safety analyses, regulatory perspectives on regenerative medicine, advances in pigmentary and procedural care, and health‑equity research that …
Welcome to "JDD January 2026 Issue Highlights," your guided tour through this month's must-read studies, curated by the Journal of Drugs in Dermatology Editorial Team. This issue carries a Special Focus on Aesthetic Treatments, bringing together practical safety analyses, regulatory perspectives on regenerative medicine, advances in pigmentary and procedural care, and health‑equity research that … 
Introduction
Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis characterized by rapidly enlarging, painful ulcers with violaceous and undermined borders. It is commonly associated with systemic disorders, including rheumatoid arthritis, hematologic malignancies, and inflammatory bowel disease (IBD).¹ While PG often correlates with IBD flares, its pathogenesis is not well understood. C … 
GLP-1 receptor agonists are revolutionizing the treatment of type 2 diabetes and obesity. With widespread consumer advertising campaigns, GLP-1 usage is becoming commonplace. National polls show up to one-fifth of American adults have tried GLP-1s for weight loss or to address health conditions, such as heart disease. As the understanding of GLP-1s deepens, so does their potential. Since recent re … 
Hyaluronic acid (HA) fillers are widely used in aesthetic medicine for facial rejuvenation, volumization, and wrinkle treatment. Noninflammatory nodules after HA filler injection are a relatively common phenomenon and a result of poor technique or a large volume bolus in one area.¹ Unlike these nodules, delayed-onset nodules (DON) occur in 0.5% of injections and can be inflammatory, granulomatou … 
We’re closing out 2025 with an immunodermatology–focused issue of the Journal of Drugs in Dermatology. From incretin-based therapies for hidradenitis suppurativa (HS) to real-world data on cardiometabolic risk in inflammatory skin disease, these Editor’s Picks connect skin and systemic health with practical pearls for clinic.
GLP-1 Receptor Agonists in Hidradenitis Suppurativa: A …